Curaleaf (OTCMKTS:CURLF) Announces Quarterly Earnings Results, Beats Estimates By $0.25 EPS

Curaleaf (OTCMKTS:CURLF) released its quarterly earnings results on Wednesday. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.25, Zacks reports. Curaleaf had a negative return on equity of 8.11% and a negative net margin of 7.76%.

Curaleaf Price Performance

CURLF traded down $0.66 on Wednesday, hitting $8.35. 153,036 shares of the company’s stock traded hands, compared to its average volume of 314,353. The company’s 50 day simple moving average is $7.07 and its 200-day simple moving average is $7.68. The company has a current ratio of 1.56, a quick ratio of 0.74 and a debt-to-equity ratio of 1.05. Curaleaf has a one year low of $4.56 and a one year high of $15.15. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -21.41 and a beta of 1.56.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Curaleaf from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Three research analysts have rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Strong Buy”.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.